Application of Nanotechnology in Cancer Therapy: Potential and Limitations
Journal of Current Oncological Trends · 2024
DOI: 10.4103/jcot.jcot_17_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Oncological Trends, 2024. Verfasst von Sougata Mondal und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Nanotechnology is an emerging platform for increasing the selectivity and potency of different treatment modalities for progressive cancer therapy. Architectures of nanoscale are successively explored for delivery of water-insoluble drug molecules as well as malignant cell targeting, avoiding nonspecific toxicity. Nanotechnology can also help in the synergistic application of different therapeutics. Despite numerous advantages, the clinical application of nanoformulations is limited due to poor biodistribution, failure of enhanced permeability and retention-dependent targeting, and change in biophysical properties in the physiological environment. In this review, we summarized different promising properties of nanotechnology in combination with relevant challenges, with the help of corresponding literature and current status.
Zitieren
APA
Mondal, S., Basu, D., Maiti, B., Ghosh, O., & Ghosh, S. (2024). Application of Nanotechnology in Cancer Therapy: Potential and Limitations. Journal of Current Oncological Trends. https://doi.org/10.4103/jcot.jcot_17_24
Vancouver
Mondal S, Basu D, Maiti B, Ghosh O, Ghosh S. Application of Nanotechnology in Cancer Therapy: Potential and Limitations. Journal of Current Oncological Trends. 2024. doi:10.4103/jcot.jcot_17_24
BibTeX
@article{Mondal2024,
author = {Mondal, Sougata and Basu, Debapriya and Maiti, Bidisha and Ghosh, Oyendrila and Ghosh, Supratim},
title = {Application of Nanotechnology in Cancer Therapy: Potential and Limitations},
journal = {Journal of Current Oncological Trends},
year = {2024},
doi = {10.4103/jcot.jcot_17_24}
}
EUVIMED